This__O project__O developed__O a__O new__O tamponade__O agent__O to__O enhance__O the__O clinical__O outcome__O after__O treatment__O of__O retinal__O detachments.__O
Standard__O tamponade__O agents__O are__O based__O on__O silicone__O oils__O which__O can__O emulsify__O in__O the__O eye__O and__O cause__O adverse__O side__O effects.__O
The__O underpinning__O research__O provided__O proof__O of__O principle__O that__O a__O silicone__O oil__O with__O an__O increased__O extensional__O viscosity__O had__O an__O increased__O resistance__O to__O emulsification.__O
This__O was__O achieved__O by__O the__O addition__O of__O a__O low__O percentage__O of__O a__O very__O high__O molecular__O weight__O polymer__O of__O the__O same__O chemistry__O to__O the__O silicone__O oil.__O
Following__O on__O from__O this__O the__O UoL__O established__O that__O the__O extensional__O viscosity__O property__O of__O the__O blend__O also__O made__O the__O material__O easier__O to__O inject__O in__O comparison__O with__O an__O equivalent__O silicone__O oil__O with__O the__O same__O shear__O viscosity__O but__O without__O the__O high__O molecular__O weight__O additive.__O
An__O additional__O benefit__O of__O this__O approach__O is__O that__O since__O there__O has__O been__O no__O chemically__O different__O material__O added__O to__O the__O clinical__O grade__O silicone__O oil__O the__O regulatory__O requirements__O were__O easier.__O
In__O 2007__O a__O collaboration__O was__O established__O with__O Fluoron__B-PER GmbH,__I-PER a__O silicone__O oil__O tamponade__O manufacturer,__O to__O develop__O the__O proof__O of__O principle__O prototype__O into__O a__O clinical__O grade__O product.__O
Fluoron__B-ORG GmbH__I-ORG licensed__O the__O technology__O from__O the__O University__O and__O have__O since__O contributed__O a__O minimum__O payment__O of__O &#163;10k__B-ORG pa__O and__O paid__O all__O patent__O costs.__O
Fluoron__B-ORG GmbH__I-ORG launched__O the__O product__O named__O Siluron&#174;__B-ORG 2000__I-ORG in__O 2008__O (EC__B-ORG certification:__O CE__O 575554)__O [4,6].__O
It__O accounted__O for__O 32%__O of__O its__O sales__O by__O units__O in__O the__O period__O 2008-13__O with__O 34,208__O sales__O by__O 30th__O September__O 2013__O [11].__O
A__O second__O product__O named__O Siluron&#174;__B-ORG Xtra__I-ORG based__O on__O this__O technology__O was__O launched__O for__O sale__O in__O July__O 2013__O (EC__O certification:__O CE__O 575554).__O
This__O product__O has__O 10%__O of__O the__O high__O molecular__O weight__O additive__O further__O increasing__O the__O resistance__O to__O emulsification__O while__O maintaining__O the__O ease__O of__O injection__O within__O the__O range__O of__O current__O clinical__O products.__O
Fluoron__B-ORG GmbH__I-ORG have__O brought__O this__O second__O product__O to__O market__O in__O response__O to__O requests__O from__O vitreoretinal__O surgeons__O [5]__O and__O it__O has__O sold__O 1,145__O units__O part__O way__O through__O its__O first__O year__O of__O introduction__O [11].__O
These__O products__O have__O enabled__O Fluoron__O to__O gain__O new__O customers__O and__O reduce__O complaint__O rates__O by__O 40%__O [11].__O
The__O ultimate__O beneficiaries__O will__O be__O patients.__O
Current__O tamponade__O agents__O are__O either__O made__O from__O 1000mPas__O silicone__O oil__O that__O is__O known__O to__O emulsify__O in__O the__O eye__O and__O cause__O adverse__O effects__O for__O the__O patient__O or__O 5000mPas__O silicone__O oil__O that__O is__O very__O viscous__O and__O difficult__O to__O inject.__O
All__O silicone__O oils__O are__O currently__O removed__O after__O 3-6__O months__O because__O of__O the__O risk__O of__O emulsification__O leading__O to__O complications.__O
The__O new__O Siluron&#174;__B-ORG 2000__I-ORG has__O a__O shear__O viscosity__O of__O 2000mPas__O making__O it__O easier__O to__O inject__O than__O 5000mPas__O oil__O but__O because__O of__O the__O increased__O emulsification__O resistance__O will__O be__O less__O likely__O to__O cause__O adverse__O effects__O to__O the__O patient__O [9,10].__B-MISC
Another__O major__O advantage__O of__O Siluron&#174;__B-ORG 2000__I-ORG is__O that__O its__O extensional__O viscosity__O makes__O it__O easier__O to__O inject__O than__O an__O equivalent__O oil__O meaning__O that__O smaller__O gauge__O instruments__O can__O be__O used__O to__O inject__O and__O remove__O it__O from__O the__O eye__O causing__O a__O significant__O reduction__O in__O trauma__O to__O the__O patient's__O eye__O due__O to__O the__O surgery.__O
This__O also__O fits__O very__O well__O with__O the__O general__O move,__O within__O vitreoretinal__O surgery,__O to__O the__O use__O of__O smaller__O gauge__O instruments.__O
Siluron&#174;__B-PER Xtra__I-PER has__O a__O shear__O viscosity__O of__O 5000mPas__O and__O can__O therefore__O be__O injected__O and__O removed__O using__O existing__O surgical__O equipment__O but__O has__O been__O requested__O by__O clinicians__O owing__O to__O its__O enhanced__O resistance__O to__O emulsification__O and__O thus__O improved__O clinical__O outcome__O for__O patients.__O
The__O market__O for__O silicone__O oil__O tamponades__O is__O not__O large__O but__O is__O valuable__O because__O the__O patients__O requiring__O this__O treatment__O would__O go__O blind__O if__O not__O treated.__O
The__O incidence__O of__O retinal__O detachment__O is__O reported__O as__O 1__O per__O 10,000__O of__O population__O pa__O and__O of__O these__O 15-20%__O are__O treated__O with__O silicone__O oil__O tamponades.__O
Some__O vitreoretinal__O surgeons__O will__O not__O use__O oils__O because__O of__O the__O oil__O related__O complications__O and__O therefore__O the__O availability__O of__O an__O oil__O with__O increased__O emulsification__O resistance__O is__O expected__O to__O increase__O this__O treatment__O option.__O
This__O is__O the__O first__O product__O specifically__O designed__O to__O address__O this__O problem.__O
Fluoron__B-ORG GmbH__I-ORG has__O sold__O over__O 25,000__O units__O of__O Siluron&#174;__B-ORG 2000.__O
In__O 2012__O the__O units__O were__O sold__O across__O 37__O different__O countries__O with__O the__O largest__O numbers__O going__O to__O Germany__B-LOC and__O Egypt__B-LOC and__O substantial__O numbers__O going__O to__O Singapore,__B-ORG Italy,__I-ORG Belgium__I-ORG and__O Switzerland.__B-LOC
They__O have__O recently__O (August__B-ORG 2013)__O received__O a__O licence__O to__O sell__O Siluron&#174;__B-ORG 2000__I-ORG and__O Xtra__B-ORG in__O China__B-LOC and__O believe__O this__O to__O be__O a__O substantial__O market,__O expecting__O to__O sell__O over__O 1000__O units__O in__O the__O first__O year.__O
An__O audit__O of__O its__O use__O in__O St__B-ORG Paul's__I-ORG Eye__I-ORG Unit__I-ORG at__I-ORG Royal__I-ORG Liverpool__I-ORG University__I-ORG Hospital__I-ORG on__O 20__O patients__O reported__O "Clinically__O it__O proved__O easy__O to__O inject__O and__O remove__O in__O a__O small-gauge__O setup.__O
Anatomical__O success__O rates__O were__O comparable__O to__O our__O experience__O with__O standard__O 5000cst__O silicone__O oil,__O so__O was__O its__O safety__O profile."__O
[7].__O
